<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001489</url>
  </required_header>
  <id_info>
    <org_study_id>950008</org_study_id>
    <secondary_id>95-N-0008</secondary_id>
    <nct_id>NCT00001489</nct_id>
  </id_info>
  <brief_title>Effect of Vigabatrin on Brain Blood Flow and Glucose Metabolism</brief_title>
  <official_title>The Effect of Vigabatrin on Cerebral Blood Flow and Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study is designed to test the effects of vigabatrin (gamma-vinyl-GABA) an experimental
      drug used for the treatment of epilepsy. The study will use positron emission tomography (PET
      scan) to detect areas of the brain receiving increased blood flow and using increased amounts
      of glucose. Increases in blood flow and glucose use are good indicators of brain activity.

      Researchers are interested in determining the effects of Vigabatrin on brain blood flow and
      glucose use.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This double-blind placebo-controlled parallel design protocol will investigate the effects of
      gamma-vinyl-GABA (vigabatrin--GVG) an experimental antiepileptic drug, on cerebral glucose
      metabolism (LCMRglc), blood flow (CBF), and seizure frequency, in patients with uncontrolled
      complex partial (CPS) and secondary generalized seizures (GTCS). Positron Emission Tomography
      (PET) will be used to measure CBF and LCMRglc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 1994</start_date>
  <completion_date>August 2000</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment>20</enrollment>
  <condition>Epilepsy</condition>
  <condition>Epilepsy, Complex Partial</condition>
  <eligibility>
    <criteria>
      <textblock>
        Localization-related epilepsy.

        Uncontrolled seizures.

        Ability to tolerate tegretol monotherapy.

        No systemic illness requiring drug therapy.

        No illness that might be made worse by vigabatrin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institute of Neurological Disorders and Stroke (NINDS)</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ben-Menachem E, Persson LI, Schechter PJ, Haegele KD, Huebert N, Hardenberg J, Dahlgren L, Mumford JP. The effect of different vigabatrin treatment regimens on CSF biochemistry and seizure control in epileptic patients. Br J Clin Pharmacol. 1989;27 Suppl 1:79S-85S.</citation>
    <PMID>2474312</PMID>
  </reference>
  <reference>
    <citation>Browne TR, Mattson RH, Penry JK, Smith DB, Treiman DM, Wilder BJ, Ben-Menachem E, Napoliello MJ, Sherry KM, Szabo GK. Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology. 1987 Feb;37(2):184-9.</citation>
    <PMID>3808298</PMID>
  </reference>
  <verification_date>August 1999</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>December 9, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2002</study_first_posted>
  <last_update_submitted>March 3, 2008</last_update_submitted>
  <last_update_submitted_qc>March 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 4, 2008</last_update_posted>
  <keyword>Cerebral Metabolism</keyword>
  <keyword>Complex Partial Seizures</keyword>
  <keyword>Epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsy, Complex Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vigabatrin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

